Eloxx Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 18
- Market Cap
- -
- Website
- http://www.eloxxpharma.com
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Study of ELX-02 in Patients With Alport Syndrome
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Eloxx Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05448755
- Locations
- 🇦🇺
Monash Medical Center, Clayton, Victoria, Australia
🇦🇺Royal Children's Hospital, Parkville, Victoria, Australia
🇬🇧Royal Free Hospital, London, United Kingdom
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Eloxx Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04135495
- Locations
- 🇺🇸
Long Beach Memorial, Long Beach, California, United States
🇺🇸Stanford School of Medicine, Palo Alto, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Eloxx Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04126473
- Locations
- 🇦🇺
The Royal Prince Alfred Hospital, Camperdown, New South Whales, Australia
🇦🇺The Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Eloxx Pharmaceuticals, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04069260
- Locations
- 🇨🇦
McGill University Health Center, Montréal, Quebec, Canada
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Eloxx Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03776539
- Locations
- 🇺🇸
Inventiv Health Clinical -Research Pharmacy Unit, Miami, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
- Prev
- 1
- 2
- Next